Agilent Technologies (NYSE:A) Given New $150.00 Price Target at Citigroup

Agilent Technologies (NYSE:AGet Rating) had its price objective boosted by Citigroup from $145.00 to $150.00 in a research note published on Tuesday morning, The Fly reports. They currently have a neutral rating on the medical research company’s stock.

Several other research firms have also recently commented on A. KeyCorp boosted their target price on Agilent Technologies from $155.00 to $165.00 and gave the stock an overweight rating in a research report on Tuesday. Credit Suisse Group began coverage on Agilent Technologies in a research report on Wednesday, August 24th. They set an outperform rating and a $165.00 target price for the company. StockNews.com began coverage on Agilent Technologies in a research report on Wednesday, October 12th. They set a strong-buy rating for the company. Wells Fargo & Company boosted their target price on Agilent Technologies from $130.00 to $135.00 and gave the stock an equal weight rating in a research report on Wednesday, August 17th. Finally, Bank of America boosted their target price on Agilent Technologies from $148.00 to $155.00 and gave the stock a buy rating in a research report on Wednesday, August 17th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $157.00.

Agilent Technologies Stock Up 8.1 %

A stock opened at $156.86 on Tuesday. The stock’s fifty day simple moving average is $133.55 and its two-hundred day simple moving average is $128.29. The company has a current ratio of 1.94, a quick ratio of 1.41 and a debt-to-equity ratio of 0.54. Agilent Technologies has a 1-year low of $112.52 and a 1-year high of $162.62. The stock has a market cap of $46.44 billion, a P/E ratio of 35.73, a P/E/G ratio of 2.67 and a beta of 1.06.

Agilent Technologies (NYSE:AGet Rating) last issued its earnings results on Monday, November 21st. The medical research company reported $1.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.14. The firm had revenue of $1.85 billion for the quarter, compared to analyst estimates of $1.76 billion. Agilent Technologies had a return on equity of 28.46% and a net margin of 19.94%. The business’s revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.21 earnings per share. Analysts expect that Agilent Technologies will post 5.07 EPS for the current year.

Agilent Technologies Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 25th. Shareholders of record on Tuesday, January 3rd will be given a dividend of $0.225 per share. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.21. The ex-dividend date is Friday, December 30th. This represents a $0.90 dividend on an annualized basis and a yield of 0.57%. Agilent Technologies’s dividend payout ratio is presently 19.13%.

Insider Buying and Selling at Agilent Technologies

In other news, CEO Michael R. Mcmullen sold 6,775 shares of the stock in a transaction that occurred on Wednesday, November 16th. The stock was sold at an average price of $148.19, for a total value of $1,003,987.25. Following the completion of the transaction, the chief executive officer now owns 270,896 shares of the company’s stock, valued at approximately $40,144,078.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Michael R. Mcmullen sold 6,775 shares of the stock in a transaction that occurred on Wednesday, November 16th. The stock was sold at an average price of $148.19, for a total value of $1,003,987.25. Following the completion of the transaction, the chief executive officer now owns 270,896 shares of the company’s stock, valued at approximately $40,144,078.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Michael Tang sold 3,600 shares of the stock in a transaction that occurred on Tuesday, November 1st. The stock was sold at an average price of $139.50, for a total value of $502,200.00. Following the completion of the transaction, the senior vice president now directly owns 43,280 shares of the company’s stock, valued at approximately $6,037,560. The disclosure for this sale can be found here. Insiders sold 35,309 shares of company stock valued at $4,846,147 in the last 90 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in Agilent Technologies by 1.9% during the 3rd quarter. BlackRock Inc. now owns 32,943,190 shares of the medical research company’s stock valued at $4,004,242,000 after buying an additional 629,153 shares in the last quarter. Vanguard Group Inc. increased its position in Agilent Technologies by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 24,955,720 shares of the medical research company’s stock valued at $3,033,368,000 after buying an additional 257,455 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Agilent Technologies by 1.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 16,652,764 shares of the medical research company’s stock valued at $1,977,848,000 after buying an additional 223,279 shares in the last quarter. State Street Corp boosted its stake in Agilent Technologies by 0.6% during the 3rd quarter. State Street Corp now owns 13,152,295 shares of the medical research company’s stock valued at $1,598,661,000 after purchasing an additional 73,495 shares during the last quarter. Finally, Wellington Management Group LLP boosted its stake in Agilent Technologies by 18.5% during the 1st quarter. Wellington Management Group LLP now owns 10,826,141 shares of the medical research company’s stock valued at $1,432,622,000 after purchasing an additional 1,691,006 shares during the last quarter.

Agilent Technologies Company Profile

(Get Rating)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.

Featured Stories

The Fly logo

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.